NIOX Group Plc (FRA:82C)

Market Cap	279.62M -2.8%
Revenue (ttm)	55.82M +24.9%
Net Income	8.02M -40.2%
EPS	0.02 -36.7%
Shares Out	n/a
PE Ratio	34.85
Forward PE	19.47
Dividend	0.01 (2.41%)
Ex-Dividend Date	May 15, 2025

Volume	n/a
Average Volume	n/a
Open	0.6650
Previous Close	0.6500
Day's Range	0.6400 - 0.6650
52-Week Range	0.5850 - 0.8850
Beta	n/a
RSI	40.45
Earnings Date	Mar 24, 2026

About NIOX Group

NIOX Group Plc engages in the design, development, and commercialization of medical devices for asthma diagnosis, monitoring, and management worldwide. It offers NIOX VERO, a non-invasive and point-of-care system that comprises a small portable device and a range of consumables, including sensors, individual disposable mouthpieces, and breathing handles for the measurement of Fractional Exhaled Nitric Oxide (FeNO) level in patients. The company was formerly known as Circassia Group Plc and changed its name to NIOX Group Plc in September 2022. N...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2006
• Employees: 91
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 82C

Financial Performance

In 2025, NIOX Group's revenue was 48.70 million, an increase of 16.51% compared to the previous year's 41.80 million. Earnings were 7.00 million, an increase of 89.19%.

Financial numbers in GBP